Overview

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cediranib